Insider purchase: Zivo Bioscience (ZIVO) CEO adds 11,709 shares

Rhea-AI Filing Summary

Zivo Bioscience, Inc. President and CEO John B. Payne reported an open-market purchase of company stock. On 01/26/2026, he bought 11,709 shares of common stock at $8.54 per share. Following this transaction, he directly owns 19,618 shares of Zivo Bioscience common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAYNE JOHN BERNARD

(Last) (First) (Middle)

2125 BUTTERFIELD DRIVE

SUITE 100

(Street)

TROY MI 48084

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ ZIVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		P		11,709	A	$8.54	19,618	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John B. Payne	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zivo Bioscience (ZIVO) disclose in this Form 4?

Zivo Bioscience disclosed that its President and CEO, John B. Payne, purchased 11,709 shares of common stock. The shares were acquired in an open-market transaction on January 26, 2026, and are reported as directly owned by him.

How many Zivo Bioscience (ZIVO) shares did the CEO buy and at what price?

John B. Payne bought 11,709 shares of Zivo Bioscience common stock at a price of $8.54 per share. This open-market purchase is reported under transaction code "P" for a buy in the Form 4 filing.

What is the CEO's total Zivo Bioscience (ZIVO) share ownership after this trade?

After the reported transaction, John B. Payne beneficially owns 19,618 shares of Zivo Bioscience common stock. The filing indicates these shares are held with direct ownership, meaning they are attributed personally to him.

What does transaction code "P" mean in the Zivo Bioscience (ZIVO) Form 4?

Transaction code "P" in the Form 4 indicates an open-market or private purchase of securities. In this case, it shows that John B. Payne acquired Zivo Bioscience common stock by buying shares rather than selling or receiving them through an award.

What roles does John B. Payne hold at Zivo Bioscience (ZIVO)?

John B. Payne is reported as both a Director and an Officer of Zivo Bioscience, serving as President and CEO. His dual roles and share purchase are disclosed to provide transparency about insider ownership and trading activity.

Is the Zivo Bioscience (ZIVO) CEO's ownership direct or indirect after this transaction?

The Form 4 indicates that John B. Payne’s 19,618 Zivo Bioscience shares are held with direct ownership, marked with "D". No nature of indirect beneficial ownership, such as through a trust or entity, is listed in the filing.